Korro Bio, Inc. (KRRO) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth No data; EPS growth Lose.
14/45
1.6 / 5 stars
All 45 Win/Lose results and 75 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 5 wins, 6 losses, 1 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinKRRO / S&P 16.43% / 15.20% |
LoseKRRO / S&P -62.08% / 15.00% |
LoseKRRO / S&P 2.56% / 50.40% |
| 2026-Q11/3 |
WinKRRO / S&P 41.32% / -4.33% |
LoseKRRO / S&P -20.31% / 11.30% |
LoseKRRO / S&P 23.62% / 27.70% |
| 2025-Q42/3 |
LoseKRRO / S&P -83.27% / 2.65% |
WinKRRO / S&P 181.46% / 9.00% |
WinKRRO / S&P 32.80% / 13.40% |
| 2025-Q31/2 |
WinKRRO / S&P 283.43% / 8.12% |
No dataKRRO / S&P / 4.61% |
LoseKRRO / S&P -106.69% / 13.45% |
| 2025-Q20/2 |
LoseKRRO / S&P -28.26% / 10.94% |
No dataKRRO / S&P / 4.83% |
LoseKRRO / S&P -112.51% / 10.63% |
| 2025-Q10/2 |
LoseKRRO / S&P -54.27% / -4.27% |
No dataKRRO / S&P / 4.98% |
LoseKRRO / S&P -157.18% / 10.57% |
| 2024-Q41/2 |
WinKRRO / S&P 13.91% / 2.41% |
No dataKRRO / S&P / 5.25% |
LoseKRRO / S&P -82.37% / 6.15% |
| 2024-Q30/2 |
LoseKRRO / S&P -1.33% / 5.89% |
No dataKRRO / S&P / 5.89% |
LoseKRRO / S&P -132.98% / 6.11% |
| 2024-Q20/2 |
LoseKRRO / S&P -62.37% / 4.28% |
No dataKRRO / S&P / 5.38% |
LoseKRRO / S&P -121.51% / 5.12% |
| 2024-Q11/1 |
WinKRRO / S&P 87.77% / 10.56% |
No dataKRRO / S&P / 5.71% |
No dataKRRO / S&P / 5.59% |
| 2023-Q41/1 |
WinKRRO / S&P 159.08% / 11.69% |
No dataKRRO / S&P / 6.81% |
No dataKRRO / S&P / 7.78% |
| 2023-Q31/1 |
WinKRRO / S&P 6.94% / -3.27% |
No dataKRRO / S&P / 7.52% |
No dataKRRO / S&P / -5.03% |
| 2023-Q20/1 |
LoseKRRO / S&P -31.21% / 8.74% |
No dataKRRO / S&P / 9.50% |
No dataKRRO / S&P / -8.57% |
| 2023-Q10/1 |
LoseKRRO / S&P -86.94% / 7.50% |
No dataKRRO / S&P / 10.77% |
No dataKRRO / S&P / -15.69% |
| 2022-Q41/2 |
WinKRRO / S&P 115.08% / 7.56% |
LoseKRRO / S&P -100.00% / 11.88% |
No dataKRRO / S&P / -17.99% |
| 2022-Q31/2 |
WinKRRO / S&P 19.33% / -4.88% |
LoseKRRO / S&P -100.00% / 13.47% |
No dataKRRO / S&P / -1.41% |
| 2022-Q20/2 |
LoseKRRO / S&P -29.25% / -16.10% |
LoseKRRO / S&P -100.00% / 13.71% |
No dataKRRO / S&P / 11.04% |
| 2022-Q10/2 |
LoseKRRO / S&P -58.67% / -4.60% |
LoseKRRO / S&P -72.60% / 15.97% |
No dataKRRO / S&P / 42.23% |
| 2021-Q40/2 |
LoseKRRO / S&P -27.34% / 11.03% |
LoseKRRO / S&P -61.96% / 15.00% |
No dataKRRO / S&P / 96.40% |
| 2021-Q30/2 |
LoseKRRO / S&P -29.12% / 0.58% |
LoseKRRO / S&P -24.34% / 10.77% |
No dataKRRO / S&P / 69.42% |
| 2021-Q20/2 |
LoseKRRO / S&P 4.84% / 8.55% |
LoseKRRO / S&P -21.17% / 6.58% |
No dataKRRO / S&P / 51.81% |
| 2021-Q10/1 |
LoseKRRO / S&P -73.06% / 6.17% |
No dataKRRO / S&P / -1.06% |
No dataKRRO / S&P / 7.39% |
| 2020-Q41/1 |
WinKRRO / S&P 83.55% / 12.15% |
No dataKRRO / S&P / -3.72% |
No dataKRRO / S&P / -33.42% |
| 2020-Q30/1 |
LoseKRRO / S&P -17.38% / 8.93% |
No dataKRRO / S&P / -2.04% |
No dataKRRO / S&P / -27.10% |
| 2020-Q21/1 |
WinKRRO / S&P 30.54% / 20.54% |
No dataKRRO / S&P / -0.46% |
No dataKRRO / S&P / -27.11% |
| 2020-Q11/1 |
WinKRRO / S&P 1.60% / -19.60% |
No dataKRRO / S&P / 3.47% |
No dataKRRO / S&P / -14.75% |
| 2019-Q40/0 |
No dataKRRO / S&P / 9.07% |
No dataKRRO / S&P / 5.36% |
No dataKRRO / S&P / 2.99% |
| 2019-Q30/0 |
No dataKRRO / S&P / 1.70% |
No dataKRRO / S&P / 5.02% |
No dataKRRO / S&P / 0.21% |
| 2019-Q20/0 |
No dataKRRO / S&P / 4.30% |
No dataKRRO / S&P / 6.64% |
No dataKRRO / S&P / 8.65% |
| 2019-Q10/0 |
No dataKRRO / S&P / 13.65% |
No dataKRRO / S&P / 8.12% |
No dataKRRO / S&P / 14.29% |
| 2018-Q40/0 |
No dataKRRO / S&P / -13.52% |
No dataKRRO / S&P / 9.05% |
No dataKRRO / S&P / 18.23% |
| 2018-Q30/0 |
No dataKRRO / S&P / 7.71% |
No dataKRRO / S&P / 10.21% |
No dataKRRO / S&P / 19.06% |
| 2018-Q20/0 |
No dataKRRO / S&P / 3.43% |
No dataKRRO / S&P / 9.03% |
No dataKRRO / S&P / 14.46% |
| 2018-Q10/0 |
No dataKRRO / S&P / -0.76% |
No dataKRRO / S&P / 7.68% |
No dataKRRO / S&P / 12.46% |
| 2017-Q40/0 |
No dataKRRO / S&P / 6.64% |
No dataKRRO / S&P / 7.03% |
No dataKRRO / S&P / 13.82% |
| 2017-Q30/0 |
No dataKRRO / S&P / 4.48% |
No dataKRRO / S&P / 5.68% |
No dataKRRO / S&P / 17.57% |
| 2017-Q20/0 |
No dataKRRO / S&P / 3.09% |
No dataKRRO / S&P / 4.83% |
No dataKRRO / S&P / 17.74% |
| 2017-Q10/0 |
No dataKRRO / S&P / 6.07% |
No dataKRRO / S&P / 3.67% |
No dataKRRO / S&P / 13.32% |
| 2016-Q40/0 |
No dataKRRO / S&P / 3.82% |
No dataKRRO / S&P / 2.09% |
No dataKRRO / S&P / 7.05% |
| 2016-Q30/0 |
No dataKRRO / S&P / 3.85% |
No dataKRRO / S&P / 0.20% |
No dataKRRO / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | KRRO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -42.55% | 20.78% |
| Annualized return | -42.55% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | KRRO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -96.65% | 83.14% |
| Annualized return | -49.29% | 12.86% |
10Y · 2019-10-03 to 2026-08-27
| Metric | KRRO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -98.06% | 319.30% |
| Annualized return | -32.60% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |